Differences

This shows you the differences between two versions of the page.

--- documentation:oncology:meeting_notes_2019_jun-25 [2019/06/27 14:09] – mgurley
+++ documentation:oncology:meeting_notes_2019_jun-25 [2019/06/27 14:10] (current) – mgurley
@@ Line 11: / Line 11: @@
     * The group was asked for volunteers to write SQL to derive Hemonc.org oncology drug regimens from low-level DRUG_EXPOSURE and EPISODE oncology diagnosis entries.  Michael Gurley pointed to the following paper as a starting point: https://ascopubs.org/doi/pdf/10.1200/CCI.17.00002
     * Dmytry Dymshyts expressed doubt about the possibility of derivation of oncology drug regimens from discrete DRUG_EXPOSURE data and EPISODE oncology diagnosis entries.
-    * The group agreed that validation of derivation will need to be compered to gold standard manually chart abstracted oncology drug regimens.  Possibly from clinical trials or registry patients.
+    * The group agreed that validation of derivation will need to be compared to gold standard manually chart abstracted oncology drug regimens.  Possibly from clinical trials or registry patients.
     * Michael Gurley pointed out that some institutions' source systems will have pre-derived oncology drug regimens within their oncology drug regimen order template systems.  These folks are the "lucky ones".
     * Michael Gurley mentioned that Jeremy Warner (one of the principal architects of Hemonc.org)  thinks that the use of NLP against oncologist progress notes will be necessary to derive oncology drug regimens.